Menopause Hormone Therapy: Benefits, Risks, Timing, and Routes

Two decades of contradictory headlines have left many women either afraid of hormone therapy or convinced it is a general-purpose tonic. Neither is accurate, and the distinctions that resolve most of it are not complicated.

First distinction: systemic or local

Systemic hormone therapy circulates through the body and is used for symptoms that are themselves systemic — hot flashes, night sweats, and the sleep disruption they cause. Local vaginal therapy treats vaginal dryness, irritation, and pain with intercourse, and is given at much lower doses directed at the tissue itself.

These are not two strengths of the same decision. A woman whose only troublesome symptom is vaginal dryness usually does not need systemic therapy, and the risk discussion that applies to systemic estrogen does not transfer wholesale to low-dose vaginal treatment. When you read that hormone therapy carries a particular risk, the first thing to establish is which of the two the statement is about.

What hormone therapy is genuinely good at

The position statement puts it directly: hormone therapy “remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.” For women whose lives are disrupted by hot flashes and night sweats, treatment can also improve sleep, fatigue, mood, and overall quality of life.

Those are the claims that rest on the strongest evidence. Broader promises — that hormone therapy will prevent dementia, reverse aging, or serve as general cardiovascular prevention — are not on the same footing, and the cognitive question in particular remains unsettled.

Timing: the part that changes the answer

The 2022 hormone therapy position statement of The North American Menopause Society states that “[f]or women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome VMS and prevention of bone loss.” The wording is worth reading closely: it is or, not and.

The statement is equally specific about the other side: for women who begin hormone therapy more than 10 years from menopause onset, or who are older than 60, “the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia.” Those four named risks are the substance of the concern, and they are worth knowing by name rather than as a general warning.

Read together, the two clauses overlap rather than partitioning women neatly: because each is worded as or, a woman who is under 60 but more than 10 years past her last period satisfies one criterion and fails the other. The position statement does not resolve that by assigning her to a group. What it recommends is risk stratification by age and time since menopause, with treatment individualized on the best available evidence and periodic reevaluation of the benefits and risks of continuing. Meeting one criterion and not the other is therefore the situation that calls for stratified individual assessment — not automatic inclusion, and not automatic refusal.

The reasoning is the timing hypothesis: the same treatment behaves differently depending on how long the body has been without estrogen. Beginning therapy nearer the transition is associated with the greatest symptom relief and few adverse events; beginning it once atherosclerosis and vascular aging are further advanced shifts the calculation.

Where specialists actually disagree

The 10-year and age-60 framing is contested at the edges, and it is worth knowing that the debate is live rather than hearing only one side.

The Menopause Society's 2022 position statement moved away from an arbitrary age-based cutoff for initiating or continuing therapy, toward individualized assessment — recognising that hot flashes which began in a woman's late forties can persist into her sixties and beyond, and that some symptomatic women benefit from treatment started or continued past 60.

Going further, Taylor and Davis argued in The Lancet Diabetes & Endocrinology in 2025 that the post-Women's Health Initiative limits have had a cost of their own: women with troublesome symptoms who fall outside those limits are often simply denied therapy, and that women who might benefit from its protective effect against bone loss and fracture are not offered it. That is a serious argument from serious researchers, and it has not been settled.

What follows for a reader is not that the limits are wrong, but that falling outside them is a reason for careful individual assessment rather than automatic refusal.

Route and formulation

Estrogen can be taken orally or delivered through the skin, and the choice is not cosmetic. The position statement is explicit that the risks of hormone therapy “differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used,” and that treatment should be individualized with periodic reassessment of the benefits and risks of continuing. It also notes that different doses, formulations, and routes may have different effects on target organs, potentially allowing options that minimize risk. Beyond that principle, a preference for transdermal rather than oral estrogen when hypertension, obesity, or diabetes is present is widely described in current clinical practice and is reported from a talk at The Menopause Society’s 2025 annual meeting by secondary coverage, not from the position statement or from a primary conference record; it is stated here as practice rather than as a graded recommendation, and it is a question to put to your prescriber rather than a rule to apply yourself. Lower effective doses are generally favored over the higher-dose oral regimens studied in the original Women's Health Initiative trials.

If you have a uterus, systemic estrogen is prescribed together with a progestogen. Estrogen alone stimulates the endometrium; the progestogen is what protects it. This is not an optional add-on, and it is one reason hormone therapy obtained without a prescribing clinician who knows your anatomy is unsafe.

What the label says now, and what it does not say

The prescribing information changed in 2026, and the change is narrower than the headlines around it. On 10 November 2025 the FDA requested labelling changes from manufacturers of menopausal hormone therapy products, following a review of the scientific literature. A request is not a label. The label changed on 12 February 2026, when the agency approved revised labelling for the first six products.

What was removed, for those six products, is specific: the risk statements for cardiovascular disease, breast cancer and probable dementia were taken out of the boxed warning, which is the agency’s most prominent warning class. The six span all four categories of menopausal hormone therapy — systemic combination oestrogen and progestogen, systemic oestrogen alone, systemic progestogen alone for a woman with a uterus who is using systemic oestrogen, and topical vaginal oestrogen. The agency said 29 companies had submitted proposed revisions at its request, so the products whose labels have changed are a first batch and not the whole market.

Four things this does not mean. It does not mean hormone therapy has been found to be without risk. It does not mean every product’s label has changed — if a specific product matters to you, the version that governs is the current prescribing information for that product. It does not remove the endometrial cancer warning, which remains on systemic oestrogen-alone therapy and is the reason a woman with an intact uterus who takes systemic oestrogen also needs a progestogen. And it does not change the individual assessment described in the rest of this page: age, how long since menopause, route, personal and family history, and what the treatment is being used for still decide whether hormone therapy is a good idea for a particular person.

What the risks actually depend on

“Is hormone therapy risky?” has no answer as asked, and the position statement says why: the risks differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Six variables, each of which can move the answer. Two women both described as “on HRT” may be on regimens with materially different risk profiles.

That is also why the statement pairs individualised treatment with periodic reevaluation of the benefits and risks of continuing. The decision is not made once. A regimen appropriate at 52 may warrant review at 58, not because a clock has run out but because the inputs have changed.

Duration, and the question of stopping

There is no fixed date at which hormone therapy must end. What the statement supports is longer duration where there is a documented indication for it — persistent bothersome vasomotor symptoms being the common one, alongside prevention of bone loss where that is the goal — combined with regular reassessment rather than indefinite repeat prescribing.

Practically, that reframes a conversation many women find frustrating. “How long can I stay on this?” is better asked as “what is this treating, is it still treating it, and what would change my risk picture?” If the indication persists and the risk profile has not shifted, the case for continuing persists with it.

When symptoms are not menopause

Hot flashes, sleep disruption, low mood and fatigue are not specific to the menopause transition, and attributing them to it by default is a recognised source of delayed diagnosis. Thyroid disease, anaemia, sleep apnoea, depression and anxiety disorders, some medications, and less commonly other endocrine conditions can produce overlapping pictures. So can two of them at once.

This matters most where the pattern is atypical: symptoms without any change in cycles, symptoms that began abruptly rather than gradually, drenching sweats confined to the night without daytime flushing, weight loss, or fever. None of those rules menopause in or out on its own, but each is a reason for the assessment to widen rather than narrow.

Starting the conversation without being dismissed

Women commonly report having menopause symptoms minimised, and there is a practical response to that which does not depend on the clinician’s attitude. Bring specifics rather than adjectives: how many hot flashes in a day, how many nights of broken sleep in a week, what you have stopped doing because of it, and how long it has been going on. Functional impact is harder to dismiss than a description of severity, and it is also the information a clinician needs to judge whether treatment is proportionate.

If you are told hormone therapy is not an option, the useful follow-up is which specific factor makes it unsuitable — a personal history, a family history, a current medication, or a general policy. Those have different answers. A general policy is worth a second opinion; a specific contraindication is worth understanding properly.

Who should not start without a fuller conversation

A personal history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, prior blood clot or stroke, active liver disease, or high baseline cardiovascular risk all change the discussion substantially. None of these is automatically an absolute bar in every circumstance, but each one moves the decision firmly into specialist territory rather than a routine prescription.

Symptoms that need attention now

Vaginal bleeding after menopause always warrants evaluation, whether or not you are on hormone therapy. So do new chest pressure or shortness of breath, one-sided leg swelling or calf pain, sudden severe headache, and any sign of stroke such as facial droop, one-sided weakness, or difficulty speaking. These are not reasons to stop a medication and wait for an appointment; they are reasons to seek care immediately.

What to bring to the visit

• The date of your last menstrual period, as accurately as you can — it drives the timing question
• Which symptom is actually bothering you most, and what it stops you doing
• Whether you have a uterus
• Blood pressure readings, weight history, and any diabetes diagnosis
• Family and personal history of breast cancer, blood clots, stroke, and heart disease
• Everything you are already taking, including supplements and anything compounded

Main takeaway

Establish first whether the problem calls for systemic or local treatment. For systemic therapy, hormone therapy is the most effective option for hot flashes and also prevents bone loss and fracture, and for women younger than 60 or within 10 years of menopause onset without contraindications the benefit–risk ratio is favorable. More than 10 years past onset, or older than 60, the balance is less favorable. Because both criteria are worded “or,” they overlap rather than sorting women into two groups, and the statement’s answer to that is stratification by age and time since menopause with periodic reassessment — while specialists are actively arguing that falling outside the limits should prompt individual evaluation rather than automatic refusal.

Sources

• FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. U.S. Food and Drug Administration, press announcement, 12 February 2026 — fda.gov. Source for: the approval of revised labelling for six products; the removal of the cardiovascular disease, breast cancer and probable dementia risk statements from the boxed warning; the four product categories; the November 2025 initiation; and the figure of 29 companies submitting proposed changes.
• Menopausal Hormone Therapies With Updated Prescribing Information. U.S. Food and Drug Administration, updated 12 February 2026 — fda.gov. Source for: which products carry updated labelling, and therefore for the statement that the six are a first batch rather than the whole market.
• HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. U.S. Food and Drug Administration, press announcement, 10 November 2025 — fda.gov. Source for: the date the agency initiated the change, which is the request stage and not the approved labelling.
• The 2022 hormone therapy position statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028 — full statement (PDF, menopause.org) · journal full text. Primary source for every quotation on this page: the efficacy statement for VMS and genitourinary syndrome of menopause and prevention of bone loss and fracture; the favorable benefit-risk ratio for women younger than 60 or within 10 years of onset without contraindications; the less favorable ratio for women more than 10 years from onset or older than 60 because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia; and the determinants of risk (type, dose, duration, route, timing of initiation, and whether a progestogen is used).
• Taylor S, Davis SR. Is it time to revisit the recommendations for initiation of menopausal hormone therapy? Lancet Diabetes Endocrinol. 2025;13(1):69–74 — abstract. Source of the argument that the 10-year and age-60 limits lead to symptomatic women being denied therapy and to women who might benefit for bone protection not being offered it.
• Timing, safety and best candidates — Faubion SS, The Menopause Society 2025 Annual Meeting — timing hypothesis; greatest symptom relief with minimal adverse events when therapy begins before age 60 or within 10 years of the final menstrual period; transdermal estrogen preferred with hypertension, obesity, or diabetes. Reported in AJMC.

Provenance

• Basis: the quoted efficacy sentence, the benefit–risk clauses and their named risks, and the risk-determinant list are taken from the 2022 position statement cited above. The argument that the initiation limits deny treatment to symptomatic women is from the Lancet source cited.
• Route of retrieval: the position-statement text was obtained through search results rendering the published statement and the journal page, not by direct retrieval of the document.
• Secondary only: the preference for transdermal over oral estrogen with hypertension, obesity or diabetes is reported from conference coverage rather than from the position statement, and is labelled on the page as practice rather than as a graded recommendation.
• Labelling change: the FDA’s request of 10 November 2025 and its approval of revised labelling for six products on 12 February 2026 — including which risk statements left the boxed warning, the four product categories, the figure of 29 companies, and the retention of the endometrial cancer warning on systemic oestrogen-alone therapy — are from the FDA’s own press announcements and its list of menopausal hormone therapies with updated prescribing information. Product-level labels were not opened for this page; the current prescribing information for a specific product governs that product.